Lilly considering a stake in Turkish drugmaker
September 6, 2011Manufacturing and Production, Research and Development, Sales and Marketing MN Pharmaceuticals, Turkey, lilly, research and development news
Eli Lilly is reportedly eyeing up a partnership with Turkish drugmaker Mustafa Nevzat Ilac Sanayi (MN Pharmaceuticals) in order to …
New API production process ‘could transform pharma’
September 6, 2011Manufacturing and Production pharma manufacturing news, pharma production
UK researchers have started work on a new project to examine a new production method that they claim could “significantly …
Roche and Evotec to develop Alzheimer’s drug
September 6, 2011Alzheimer's disease, Evotec, Roche
Roche and Evotec are to collaborate on the development and commercialisation of Evotec’s MAO-B inhibitor in patients with Alzheimer’s disease. …
Health reforms face renewed opposition
September 6, 2011Sales and Marketing NHS reforms
The government’s health reforms in England are coming under attack once again as the legislation returns to Parliament. After the …
CSL vaccine probe likely to rule out manufacturing errors
September 6, 2011Manufacturing and Production CSL Biotherapies, flu, pharma manufacturing news, vaccines
CSL Biotherapies has said that manufacturing errors were likely not to blame for febrile seizures in children who received its …
Pharma manufacturing news in brief
September 6, 2011Manufacturing and Production pharma manufacturing news
USP expands operations in India, DSM gets green light for Chinese anti-infective joint venture, plus there are updates from CMC …
Afinitor expands European licence
September 5, 2011Sales and Marketing Afinitor, Novartis, Pancreatic cancer
Novartis’ Afinitor has made further strides in the EU with an approval for use in patients with advanced pancreatic neuroendocrine …
NICE rejects three bowel cancer drugs
September 5, 2011Sales and Marketing Erbitux, NICE, Vectibix, avastin, colorectal cancer
NICE says three treatments – Roche’s Avastin, Merck KgAa’s Erbitux and Amgen’s Vectibix – are all not cost effective in …
Boehringer-Lilly won’t launch Trajenta in Germany
September 5, 2011Sales and Marketing Drug pricing, Germany, Tradjenta, Trajenta, price cuts
Boehringer Ingelheim and Lilly have decided not to launch their new diabetes drug Trajenta in Germany and say the country’s …
Crestor fails head-to-head test against Lipitor
September 2, 2011Sales and Marketing Crestor, Lipitor
AstraZeneca’s cholesterol drug Crestor has failed to show it can stop artery disease better than Pfizer’s Lipitor. The new study …
Philippines pricing controls: Pfizer ‘considered taking drugs off the market’
September 2, 2011Sales and Marketing Drug pricing, Philippines, price cuts
Pfizer considered withdrawing some of its products from the Philippines rather than face planned pricing controls, according to a US …
Zonegran study could pave way for paediatric licence
September 2, 2011Research and Development, Sales and Marketing Eisai, Zonegran, epilepsy, research and development news
Eisai’s epilepsy drug Zonegran has been found more effective than placebo in children with the neurological condition who have seizures. …
Robert Yates appointed president of Millipore
September 2, 2011Sales and Marketing appointment, sales and marketing
Merck KGaA has appointed diagnostics expert Robert Yates to the newly-created role of president at Millipore, the company it acquired …
Digital Pharma: Mobile marketing
September 1, 2011Medical Communications Digital Pharma blog, iphone, mobile, smart devices
“This, is not a phone,” said Mark Blayney Stuart holding up his BlackBerry. “It’s a very powerful computer that happens …
Ex-Pfizer employees set up new business at Sandwich
September 1, 2011Research and Development Pfizer, Sandwich, The Research Network, research and development news
Seven former Pfizer employees have set up a new business in Sandwich that will provide outsourcing services for the pharma …
Stem cell trial for stroke is safe
September 1, 2011Research and Development ReNeuron, Stem cells, stroke
A pioneering stem cell treatment for patients who have suffered a stroke has been ruled safe, and can continue to …
Rich Baptista joins Synergy Vision
September 1, 2011Medical Communications London, Quintiles, agency, appointment, chiltern, comms, communications, creativity, digital, excellence, innovation, leader, leadership, marketing, med, medical, medical communcations, success
London-based medical communications agency Synergy Vision has appointed Rich Baptista as strategic alliance director with a brief to focus on …
Tarceva approval for first-line use in EGFR lung cancer
September 1, 2011Sales and Marketing NSCLC, Roche, Tarceva
Tarceva has been granted final European approval for patients with a genetically distinct type of non-small cell lung cancer (NSCLC). …
Shire’s Firazyr gains US approval after initial setback
September 1, 2011Sales and Marketing FDA, Firazyr, Shire
After three years of waiting Shire’s Firazyr has been approved by the FDA for sudden attacks of swelling. The US …
Merck acquires cell imaging instrument maker Amnis
September 1, 2011Research and Development Merck KGaA, Millipore
EMD Millipore, the Massachussetts-based life sciences arm of Merck KGaA, has bought US cell imaging instrument maker Amnis Corporation for …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
